CN102719400B - Hla-a0201限制性抗cea抗原特异性ctl的制备方法 - Google Patents
Hla-a0201限制性抗cea抗原特异性ctl的制备方法 Download PDFInfo
- Publication number
- CN102719400B CN102719400B CN201210231576.XA CN201210231576A CN102719400B CN 102719400 B CN102719400 B CN 102719400B CN 201210231576 A CN201210231576 A CN 201210231576A CN 102719400 B CN102719400 B CN 102719400B
- Authority
- CN
- China
- Prior art keywords
- ctl
- cell
- target
- hla
- rhil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 35
- 102000036639 antigens Human genes 0.000 title claims abstract description 33
- 108091007433 antigens Proteins 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 230000000890 antigenic effect Effects 0.000 title claims abstract description 16
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 title claims abstract description 14
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title description 169
- 210000004027 cell Anatomy 0.000 claims abstract description 122
- 238000000034 method Methods 0.000 claims abstract description 69
- 230000003321 amplification Effects 0.000 claims abstract description 61
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 61
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 43
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 41
- 239000007790 solid phase Substances 0.000 claims abstract description 11
- 230000004913 activation Effects 0.000 claims abstract description 9
- 230000002494 anti-cea effect Effects 0.000 claims abstract description 9
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 6
- 210000002966 serum Anatomy 0.000 claims description 22
- 230000006698 induction Effects 0.000 claims description 21
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 19
- 239000011324 bead Substances 0.000 claims description 18
- 239000002243 precursor Substances 0.000 claims description 16
- 230000005251 gamma ray Effects 0.000 claims description 15
- 230000009849 deactivation Effects 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- 230000010261 cell growth Effects 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 230000000638 stimulation Effects 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 4
- 230000001464 adherent effect Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000005192 partition Methods 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000003252 repetitive effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 32
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 29
- 229920001184 polypeptide Polymers 0.000 abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 12
- 230000002147 killing effect Effects 0.000 abstract description 9
- 238000009169 immunotherapy Methods 0.000 abstract description 8
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 abstract 1
- 238000009395 breeding Methods 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 52
- 102000000588 Interleukin-2 Human genes 0.000 description 28
- 210000000612 antigen-presenting cell Anatomy 0.000 description 22
- 102000006354 HLA-DR Antigens Human genes 0.000 description 20
- 108010058597 HLA-DR Antigens Proteins 0.000 description 20
- 102100022297 Integrin alpha-X Human genes 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 17
- 102100033467 L-selectin Human genes 0.000 description 17
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 13
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 13
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 102000003812 Interleukin-15 Human genes 0.000 description 10
- 108090000172 Interleukin-15 Proteins 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 8
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 8
- 102100035793 CD83 antigen Human genes 0.000 description 7
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 6
- 101150013553 CD40 gene Proteins 0.000 description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
- 108010002586 Interleukin-7 Proteins 0.000 description 6
- 102000000704 Interleukin-7 Human genes 0.000 description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- -1 CD86 Proteins 0.000 description 5
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 5
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 4
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000005859 cell recognition Effects 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 231100000225 lethality Toxicity 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000017488 activation-induced cell death of T cell Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000007503 antigenic stimulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000004719 natural immunity Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 101100235006 Mus musculus Lctl gene Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210231576.XA CN102719400B (zh) | 2012-07-05 | 2012-07-05 | Hla-a0201限制性抗cea抗原特异性ctl的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210231576.XA CN102719400B (zh) | 2012-07-05 | 2012-07-05 | Hla-a0201限制性抗cea抗原特异性ctl的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102719400A CN102719400A (zh) | 2012-10-10 |
CN102719400B true CN102719400B (zh) | 2014-04-09 |
Family
ID=46945273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210231576.XA Active CN102719400B (zh) | 2012-07-05 | 2012-07-05 | Hla-a0201限制性抗cea抗原特异性ctl的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102719400B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104072599A (zh) * | 2014-06-06 | 2014-10-01 | 深圳市阳溪生物科技有限公司 | 一种多肽、采用其体外激活的树突状细胞及其用途 |
CN104830779A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于cea抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
CN105368784A (zh) * | 2015-08-26 | 2016-03-02 | 上海宇研生物技术有限公司 | 肺癌ctl细胞培养试剂盒及制备方法 |
RU2619186C1 (ru) * | 2016-03-31 | 2017-05-12 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" (НИИФКИ) | Способ получения in vitro популяций активированных антигенспецифических противоопухолевых цитотоксических Т-лимфоцитов, специфичных к эпитопам опухоль-ассоциированного антигена |
WO2019196087A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of cancer treatment using tumor antigen-specific t cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102618498A (zh) * | 2012-03-26 | 2012-08-01 | 时宏珍 | Hla-a0201限制性抗原特异性ctl制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003225866A1 (en) * | 2002-03-22 | 2003-10-13 | Aventis Pasteur, Inc. | Peptide epitopes recognized by antigen specific cd8+ t lymphocytes |
-
2012
- 2012-07-05 CN CN201210231576.XA patent/CN102719400B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102618498A (zh) * | 2012-03-26 | 2012-08-01 | 时宏珍 | Hla-a0201限制性抗原特异性ctl制备方法 |
Non-Patent Citations (8)
Title |
---|
Cassian Yee et al.Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide-MHC Tetramers.《Journal of immunology》.1999,第162卷(第4期),2227-2234. |
Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8+ CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells;Shengming Dai et al;《Jounral of Immunology》;20061231;第84卷(第12期);全文 * |
IL-15-induced human DC efficiently prime melanomaspecific naive CD8+ T cells to differentiate into CTL;Peter dubsky et al.;《Eur. J. Immunol》;20071231;第37卷(第6期);1678-1690 * |
Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers;Susann Szmania et al;《Blood》;20010831;第98卷(第3期);505-512 * |
Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide-MHC Tetramers;Cassian Yee et al;《Journal of immunology》;19991231;第162卷(第4期);2227-2234 * |
Peter dubsky et al..IL-15-induced human DC efficiently prime melanomaspecific naive CD8+ T cells to differentiate into CTL.《Eur. J. Immunol》.2007,第37卷(第6期),1678-1690. |
Shengming Dai et al.Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8+ CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells.《Jounral of Immunology》.2006,第84卷(第12期),1067-1076. |
Susann Szmania et al.Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers.《Blood》.2001,第98卷(第3期),505-512. |
Also Published As
Publication number | Publication date |
---|---|
CN102719400A (zh) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102618498B (zh) | Hla-a0201限制性抗原特异性ctl制备方法 | |
AU2006328943B2 (en) | Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer | |
JP2019504632A (ja) | Nk細胞培養用培地添加キット、及びキットを用いるnk細胞培養方法 | |
CN102719402B (zh) | Hla-a0201限制性抗hpv抗原特异性ctl的制备方法 | |
CN102719400B (zh) | Hla-a0201限制性抗cea抗原特异性ctl的制备方法 | |
CN103923880A (zh) | 一种高效增殖、靶向杀伤肿瘤的ctl制备方法 | |
CN105524884A (zh) | Hla-a0201限制性抗afp抗原特异性ctl的制备方法 | |
CN109161527A (zh) | 一种高效的nk细胞扩增方法 | |
CN104072599A (zh) | 一种多肽、采用其体外激活的树突状细胞及其用途 | |
CN102719401B (zh) | Hla-a0201限制性抗mage抗原特异性ctl的制备方法 | |
CN105524883A (zh) | Capri细胞及其制备方法 | |
CN105505871B (zh) | 一种有效扩增cik且提高其特异性杀瘤能力的方法 | |
Aglietta et al. | Ex vivo expansion of hematopoietic cells and their clinical use | |
CN104894072A (zh) | 一种自体自然杀伤细胞增殖的制备方法及其应用 | |
CN108220234A (zh) | 一种非前哨***来源抗肿瘤t细胞的体外扩增方法 | |
CN109957543A (zh) | 利用脐带血大量扩增脐血nk细胞的方法 | |
CN105969731B (zh) | 一种利用恶性胸腹水大量制备高杀伤活性til细胞的方法 | |
CN103068973A (zh) | 表达Th1特性和溶细胞性质的细胞 | |
CN105505873A (zh) | HLA-A0201限制性抗Her2-neu抗原特异性CTL的制备方法 | |
CN109535241B (zh) | Dc-cik共培养细胞及其制备方法、致敏抗原和应用 | |
CN110628717B (zh) | 一种浸润性t细胞的培养方法 | |
CN113293130B (zh) | 一种肿瘤特异性t细胞的培养方法 | |
CN105219723A (zh) | 一种用于激活胃癌特异性免疫反应的试剂盒 | |
CN105219727A (zh) | 一种用于激活结直肠癌特异性免疫反应的试剂盒 | |
CN105624110A (zh) | Hla-a0201限制性抗psa抗原特异性ctl的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121010 Assignee: Jiangsu Kang Biotechnology Co.,Ltd. Assignor: Shi Hongzhen Contract record no.: 2014320000369 Denomination of invention: Preparation method of HLA-A0201 restrictive anti-carcinoembryonic antigen (CEA) antigenic specificity cytotoxic T lymphocyte (CTL) Granted publication date: 20140409 License type: Exclusive License Record date: 20140430 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU DECON BIO-SCI-TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHI HONGZHEN Effective date: 20141230 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 211100 NANJING, JIANGSU PROVINCE TO: 211899 NANJING, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141230 Address after: 211899, Jiangsu Province, Pukou District, Nanjing Pu Road, No. 28, building 1, new mile 5 Patentee after: Jiangsu Kang Biotechnology Co.,Ltd. Address before: Jiangning District of Nanjing City, Jiangsu province 211100 General Road No. 10, Tsinghua Yuan 58 Room 201 Patentee before: Shi Hongzhen |
|
TR01 | Transfer of patent right |
Effective date of registration: 20180925 Address after: 210000 room 208, block A, building 10, Spark Road, Pukou District, Nanjing, Jiangsu. Patentee after: Lu Anjun Address before: 211899 5, building 1, new mileage 28, Tianpu Road, Pukou District, Nanjing, Jiangsu, China Patentee before: Jiangsu Kang Biotechnology Co.,Ltd. Effective date of registration: 20180925 Address after: 210000 B-6, Jiangsu science and Technology Park, 9 Wei Di Road, Qixia District, Nanjing, Jiangsu. Patentee after: De Kang cell bioengineering Center (Jiangsu) Co.,Ltd. Address before: 210000 room 208, block A, building 10, Spark Road, Pukou District, Nanjing, Jiangsu. Patentee before: Lu Anjun |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230110 Address after: Building B6-1, Jiangsu Life Science and Technology Innovation Park, No. 9, Weidi Road, Qixia District, Nanjing, Jiangsu, 210000 Patentee after: Jiangsu Kang Biotechnology Co.,Ltd. Address before: 210000 B-6, Jiangsu science and Technology Park, 9 Wei Di Road, Qixia District, Nanjing, Jiangsu. Patentee before: De Kang cell bioengineering Center (Jiangsu) Co.,Ltd. |
|
TR01 | Transfer of patent right |